Pluristyx and Humacyte Partnership to Develop Bioengineered Human Tissue for Insulin Therapy
Introduction
Seattle-based Pluristyx has announced a partnership with clinical-stage biotechnology platform Humacyte to develop a universally implantable, bioengineered human tissue for insulin-producing cells. The partnership includes access to Pluristyx’s clinical-grade PluriBank™ induced Pluripotent Stem Cell (iPSC) line to develop their BioVascular Pancreas (BVP™) product candidate. This article provides an overview of the partnership, the technology involved, and the potential implications for curing type 1 diabetes.
The Partnership
Humacyte has licensed Pluristyx’s clinical-grade PluriBank™ iPSC cell line as starting materials for manufacturing insulin-producing cells for their BVP™ product candidate. PluriBank™ iPSCs are derived from regulatory-compliant donors, extensively characterized, and expanded and banked to provide purity, identity, and genetic integrity for patient safety, available with custom edits and Pluristyx’s proprietary FailSafe® and iACT™ edits with a goal of providing improved safety and efficacy.
The Technology
The partnership includes access to Pluristyx’s panCELLa™ platform that enables the generation of “hypoimmune” cells for clinical implantation. Pluristyx, through its panCELLa™ platform, offers a portfolio of unique iPSC-based technologies, proprietary genetic engineering, and related tools, products, and services to provide end-to-end support throughout our customer’s product lifecycle. Pluristyx is the pioneering provider of immune system-tolerated and safety switch-enabled gene-edited iPSC and cell therapy solutions, accelerating customers’ path to clinic, and providing the best, fastest, and widest route to commercialization for cell-based therapeutic products.
The Implications
The combination of Humacyte’s Acellular Tissue Engineered Vessel (ATEV™) with insulin-producing cells derived from Pluristyx’s best-in-class iPSC lines brings us one step closer to curing insulin-dependent diabetes, according to Dr Benjamin Fryer, Pluristyx’s CEO. The BVP is designed to revolutionize type 1 diabetes treatment by enabling delivery and survival of insulin-producing islets inside the body. If successful, this technology could have a significant impact on the lives of the millions of patients living with type 1 diabetes worldwide.
Conclusion
Pluristyx’s partnership with Humacyte to develop bioengineered human tissue for insulin therapy is an exciting development in the field of cellular therapies. The combination of PluriBank™ iPSC cell lines and Humacyte’s ATEV™ could revolutionize the treatment of type 1 diabetes, bringing us closer to a potential cure for this debilitating disease. With ongoing research and development, we may soon see a future where insulin-producing islets derived from Pluristyx’s iPSC lines become a standard treatment option for patients with type 1 diabetes.
Long-tail Keywords
- Pluristyx
- Humacyte
- Bioengineered Human Tissue
- Insulin Therapy
- Induced Pluripotent Stem Cell (iPSC)
- Cellular Therapies
- Diabetes Treatment
- Acellular Tissue Engineered Vessel (ATEV™)
Originally Post From https://www.biospace.com/article/releases/pluristyx-announces-license-agreement-with-humacyte-to-develop-biovascular-pancreas-using-ipscs/
Read more about this topic at
The future of diabetes treatment: Is a cure possible?
FORGETDIABETES – The revolution in diabetes treatment